Aurinia Pharmaceuticals Inc. Other Comprehensive Income (Loss), Net of Tax
Aurinia Pharmaceuticals Inc. (AUPH) reported Other Comprehensive Income (Loss), Net of Tax of -$209.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2023-02-28
- Aurinia Pharmaceuticals Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-12-31 was $466.00K.
- Aurinia Pharmaceuticals Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was $326.00K.
- Aurinia Pharmaceuticals Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was -$235.00K, a 3457.14% decline year-over-year.
- Aurinia Pharmaceuticals Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-03-31 was -$766.00K, a 12866.67% decline year-over-year.
- Aurinia Pharmaceuticals Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$209.00K.
- Aurinia Pharmaceuticals Inc. other comprehensive income (loss), net of tax for fiscal 2021 was -$47.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | $466.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $792.00K derived: sum of 2 quarters · filed 2023-02-28 | $557.00K derived: sum of 3 quarters · filed 2023-02-28 | -$209.00K 10-K · filed 2023-02-28 |
| 2022-09-30 | $326.00K 10-Q · filed 2022-11-03 | $91.00K derived: sum of 2 quarters · filed 2022-11-03 | -$675.00K 10-Q · filed 2022-11-03 | -$733.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-06-30 | -$235.00K 10-Q · filed 2022-08-04 | -$1.00M 10-Q · filed 2022-08-04 | -$1.06M derived: sum of 3 quarters · filed 2023-02-28 | -$1.06M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-03-31 | -$766.00K 10-Q · filed 2022-05-10 | -$824.00K derived: sum of 2 quarters · filed 2023-02-28 | -$826.00K derived: sum of 3 quarters · filed 2023-02-28 | -$819.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | -$58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$60.00K derived: sum of 2 quarters · filed 2023-02-28 | -$53.00K derived: sum of 3 quarters · filed 2023-02-28 | -$47.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | -$2.00K 10-Q · filed 2022-11-03 | $5.00K derived: sum of 2 quarters · filed 2022-11-03 | $11.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $7.00K 10-Q · filed 2022-08-04 | $13.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $6.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |